The European Commission approved BRINSUPRI (brensocatib) as the first and only treatment for non-cystic fibrosis bronchiectasis in the EU.
NCFB is a serious and progressive lung disease that can lead to permanent lung damage.
BRINSUPRI, a DPP1 Inhibitor targeting neutrophilic inflammation, offers a new approach to treating NCFB.
First-in-Class Therapy
BRINSUPRI is the first and only approved treatment for NCFB in the European Union.
Efficacy Data
BRINSUPRI showed a 19.4% reduction in the annual rate of exacerbations compared to placebo.
Positive Patient Outcomes
Patients on BRINSUPRI experienced less decline in lung function and prolonged time to exacerbations.
Safety Profile
Common adverse reactions to BRINSUPRI include headache, hyperkeratosis, and dermatitis.
- The EC approval of BRINSUPRI marks a significant milestone for patients with NCFB in Europe, offering a potential to reshape the treatment landscape.
- 600,000 diagnosed individuals in the EU and millions undiagnosed may benefit from this groundbreaking therapy.
The approval of BRINSUPRI represents a critical advancement in treating NCFB, addressing an unmet medical need in a population with limited therapeutic options.